News

MGB Biopharma is at the forefront of efforts to tackle the global rise in antibiotic resistant infections.

Company has granted rights to develop, market and sell products and services for the detection of protein interactions.

A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.

A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.

DNA, the molecular foundation of life, has new tricks up its sleeve. The four bases from which it is composed can be artificially manipulated to construct endlessly varied forms in two and three dimensions.

Ingenza Ltd, a world leader in the application of industrial biotechnology and synthetic biology, is pleased to announce that it is collaborating with global healthcare company GlaxoSmithKline (GSK) on an innovative research project.

Study has been published in Nature Medicine.

Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).

NIH-supported findings illustrate manifold benefit of therapy.

The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.